- Title
- Hemopexin: a novel anti-inflammatory marker for distinguishing COPD from asthma
- Creator
- Winter, Natasha A.; Gibson, Peter G.; Fricker, Michael; Simpson, Jodie L.; Wark, Peter A.; McDonald, Vaness M.
- Relation
- Allergy, Asthma & Immunology Research Vol. 13, Issue 3, p. 450-467
- Publisher Link
- http://dx.doi.org/10.4168/AAIR.2021.13.3.450
- Publisher
- Korean Academy of Asthma, Allergy and Clinical Immunology
- Resource Type
- journal article
- Date
- 2021
- Description
- Purpose: Systemic inflammatory biomarkers can improve diagnosis and assessment of chronic obstructive pulmonary disease (COPD) and asthma. We aimed to validate an airway disease biomarker panel of 4 systemic inflammatory biomarkers, a2-macroglobulin, ceruloplasmin, haptoglobin and hemopexin, to establish their relationship to airway disease diagnosis and inflammatory phenotypes and to identify an optimized biomarker panel for disease differentiation. Methods: Participants with COPD or asthma were classified by inflammatory phenotypes. Immunoassay methods were used to measure levels of validation biomarkers in the sera of participants with disease and non-respiratory disease controls. Markers were analyzed individually and in combination for disease differentiation and compared to established biomarkers (C-reactive protein, interleukin-6, and white blood cell/blood eosinophil count). Results: The study population comprised of 141 COPD, 127 severe asthma, 54 mild-moderate asthma and 71 control participants. Significant differences in ceruloplasmin, haptoglobin and hemopexin levels between disease groups and between systemic inflammatory phenotypes were observed. However, no differences were found between airway inflammatory phenotypes. Hemopexin was the best performing individual biomarker and could diagnose COPD versus control participants (area under the curve [AUC], 98.3%; 95% confidence interval [CI], 96.7%-99.9%) and differentiate COPD from asthmatic participants (AUC, 97.0%; 95% CI, 95.4%-98.6%), outperforming established biomarkers. A biomarker panel, including hemopexin, haptoglobin and other established biomarkers, could diagnose asthma versus control participants (AUC, 87.5%; 95% CI, 82.8%-92.2%). Conclusions: Hemopexin can be a novel biomarker with superior diagnostic ability in differentiating COPD and asthma. We propose an anti-inflammatory axis between the airways and systemic circulation, in which hemopexin is a protective component in airway disease.
- Subject
- asthma; chronic obstructive pulmonary disease (COPD); biomarker; anti-inflammation; hemopexin; haptoglobin; diagnosis; airway inflammation; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1461553
- Identifier
- uon:46232
- Identifier
- ISSN:2092-7355
- Language
- eng
- Reviewed
- Hits: 1438
- Visitors: 1433
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|